{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:24:10Z","timestamp":1794007450520,"version":"4.8.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T00:00:00Z","timestamp":1708128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T00:00:00Z","timestamp":1708128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Novel phosphorylated-tau (p-tau) blood biomarkers (e.g., p-tau181, p-tau217 or p-tau231), are highly specific for Alzheimer\u2019s disease (AD), and can track amyloid-\u03b2 (A\u03b2) and tau pathology. However, because these biomarkers are strongly associated with the emergence of A\u03b2 pathology, it is difficult to determine the contribution of insoluble tau aggregates to the plasma p-tau signal in blood. Therefore, there remains a need for a biomarker capable of specifically tracking insoluble tau accumulation in brain.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>NTA is a novel ultrasensitive assay targeting N-terminal containing tau fragments (NTA-tau) in cerebrospinal fluid (CSF) and plasma, which is elevated in AD. Using two well-characterized research cohorts (BioFINDER-2, <jats:italic>n<\/jats:italic>\u2009=\u20091,294, and BioFINDER-1, <jats:italic>n<\/jats:italic>\u2009=\u2009932), we investigated the association between plasma NTA-tau levels and disease progression in AD, including tau accumulation, brain atrophy and cognitive decline.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We demonstrate that plasma NTA-tau increases across the AD <jats:italic>continuum<\/jats:italic>\u00b8 especially during late stages, and displays a moderate-to-strong association with tau-PET (\u03b2\u2009=\u20090.54, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) in A\u03b2-positive participants, while weak with A\u03b2-PET (\u03b2\u2009=\u20090.28, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Unlike plasma p-tau181, GFAP, NfL and t-tau, tau pathology determined with tau-PET is the most prominent contributor to NTA-tau variance (52.5% of total <jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup>), while having very low contribution from A\u03b2 pathology measured with CSF A\u03b242\/40 (4.3%). High baseline NTA-tau levels are predictive of tau-PET accumulation (<jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20090.27), steeper atrophy (<jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup>\u2009\u2265\u20090.18) and steeper cognitive decline (<jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup>\u2009\u2265\u20090.27) in participants within the AD <jats:italic>continuum<\/jats:italic>. Plasma NTA-tau levels significantly increase over time in A\u03b2 positive cognitively unimpaired (\u03b2<jats:sub>std<\/jats:sub>\u2009=\u20090.16) and impaired (\u03b2<jats:sub>std<\/jats:sub>\u2009=\u20090.18) at baseline compared to their A\u03b2 negative counterparts. Finally, longitudinal increases in plasma NTA-tau levels were associated with steeper longitudinal decreases in cortical thickness (<jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20090.21) and cognition (<jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20090.20).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our results indicate that plasma NTA-tau levels\u00a0increase across the AD <jats:italic>continuum<\/jats:italic>, especially during mid-to-late AD stages, and it is closely associated with in vivo tau tangle deposition in AD and its downstream effects. Moreover, this novel biomarker has potential as a cost-effective and easily accessible tool for monitoring disease progression and cognitive decline in clinical settings, and as an outcome measure in clinical trials which also need to assess the downstream effects of successful A\u03b2 removal.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13024-024-00707-x","type":"journal-article","created":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T04:25:59Z","timestamp":1708143959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer\u2019s Disease"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7426-678X","authenticated-orcid":false,"given":"Juan","family":"Lantero-Rodriguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Salvad\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anniina","family":"Snellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Montoliu-Gaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wagner S.","family":"Brum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Benedet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Mattsson-Carlgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontus","family":"Tideman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shorena","family":"Janelidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Palmqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Stomrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,17]]},"reference":[{"issue":"4","key":"707_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239\u201359.","journal-title":"Acta Neuropathol"},{"issue":"12","key":"707_CR2","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","volume":"58","author":"DR Thal","year":"2002","unstructured":"Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791\u2013800.","journal-title":"Neurology"},{"issue":"9533","key":"707_CR3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","volume":"368","author":"K Blennow","year":"2006","unstructured":"Blennow K, de Leon MJ, Zetterberg H. Alzheimer\u2019s disease. Lancet. 2006;368(9533):387\u2013403.","journal-title":"Lancet"},{"issue":"2","key":"707_CR4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack Jr","year":"2013","unstructured":"Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207\u201316.","journal-title":"Lancet Neurol"},{"issue":"4","key":"707_CR5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"707_CR6","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27(6):954\u201363.","journal-title":"Nat Med"},{"issue":"10","key":"707_CR7","doi-asserted-by":"publisher","first-page":"e76523","DOI":"10.1371\/journal.pone.0076523","volume":"8","author":"JE Meredith Jr","year":"2013","unstructured":"Meredith JE Jr, Sankaranarayanan S, Guss V, Lanzetti AJ, Berisha F, Neely RJ, et al. Characterization of novel CSF Tau and ptau biomarkers for Alzheimer\u2019s disease. PLoS ONE. 2013;8(10):e76523.","journal-title":"PLoS ONE"},{"issue":"6","key":"707_CR8","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.neuron.2018.02.015","volume":"97","author":"C Sato","year":"2018","unstructured":"Sato C, Barthelemy NR, Mawuenyega KG, Patterson BW, Gordon BA, Jockel-Balsarotti J, et al. Tau Kinetics in Neurons and the Human Central Nervous System. Neuron. 2018;97(6):1284-98 e7.","journal-title":"Neuron."},{"issue":"2","key":"707_CR9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00401-018-1948-2","volume":"137","author":"C Cicognola","year":"2019","unstructured":"Cicognola C, Brinkmalm G, Wahlgren J, Portelius E, Gobom J, Cullen NC, et al. Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer\u2019s disease. Acta Neuropathol. 2019;137(2):279\u201396.","journal-title":"Acta Neuropathol"},{"key":"707_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3389\/fnagi.2019.00121","volume":"11","author":"NR Barthelemy","year":"2019","unstructured":"Barthelemy NR, Mallipeddi N, Moiseyev P, Sato C, Bateman RJ. Tau phosphorylation rates measured by mass spectrometry differ in the intracellular brain vs. extracellular cerebrospinal fluid compartments and are differentially affected by alzheimer\u2019s disease. Front Aging Neurosci. 2019;11:121.","journal-title":"Front Aging Neurosci."},{"issue":"2","key":"707_CR11","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/brain\/awaa373","volume":"144","author":"K Horie","year":"2021","unstructured":"Horie K, Barthelemy NR, Sato C, Bateman RJ. CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer\u2019s disease. Brain. 2021;144(2):515\u201327.","journal-title":"Brain"},{"issue":"1","key":"707_CR12","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3233\/JAD-210677","volume":"85","author":"NR Barthelemy","year":"2022","unstructured":"Barthelemy NR, Toth B, Manser PT, Sanabria-Bohorquez S, Teng E, Keeley M, et al. Site-specific cerebrospinal fluid tau hyperphosphorylation in response to alzheimer\u2019s disease brain pathology: not all tau phospho-sites are hyperphosphorylated. J Alzheimers Dis. 2022;85(1):415\u201329.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"707_CR13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13024-022-00586-0","volume":"17","author":"J Gobom","year":"2022","unstructured":"Gobom J, Benedet AL, Mattsson-Carlgren N, Montoliu-Gaya L, Schultz N, Ashton NJ, et al. Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer\u2019s disease continuum. Mol Neurodegener. 2022;17(1):81.","journal-title":"Mol Neurodegener"},{"issue":"11","key":"707_CR14","doi-asserted-by":"publisher","first-page":"e20200861","DOI":"10.1084\/jem.20200861","volume":"217","author":"NR Barthelemy","year":"2020","unstructured":"Barthelemy NR, Horie K, Sato C, Bateman RJ. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease. J Exp Med. 2020;217(11):e20200861.","journal-title":"J Exp Med."},{"issue":"4","key":"707_CR15","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2022","unstructured":"Janelidze S, Bali D, Ashton NJ, Barthelemy NR, Vanbrabant J, Stoops E, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain. 2022;146(4):1592\u2013601.","journal-title":"Brain"},{"issue":"5","key":"707_CR16","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/alz.12841","volume":"19","author":"NJ Ashton","year":"2022","unstructured":"Ashton NJ, Puig-Pijoan A, Mila-Aloma M, Fernandez-Lebrero A, Garcia-Escobar G, Gonzalez-Ortiz F, et al. Plasma and CSF biomarkers in a memory clinic: head-to-head comparison of phosphorylated tau immunoassays. Alzheimers Dement. 2022;19(5):1913\u201324.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"707_CR17","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jalz.2018.09.010","volume":"15","author":"Z Chen","year":"2019","unstructured":"Chen Z, Mengel D, Keshavan A, Rissman RA, Billinton A, Perkinton M, et al. Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer\u2019s disease. Alzheimers Dement. 2019;15(3):487\u201396.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"707_CR18","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1093\/brain\/awab481","volume":"145","author":"A Snellman","year":"2022","unstructured":"Snellman A, Lantero-Rodriguez J, Emersic A, Vrillon A, Karikari TK, Ashton NJ, et al. N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases. Brain. 2022;145(8):2834\u201348.","journal-title":"Brain"},{"issue":"13","key":"707_CR19","doi-asserted-by":"publisher","first-page":"6084","DOI":"10.1016\/S0021-9258(17)38495-8","volume":"261","author":"I Grundke-Iqbal","year":"1986","unstructured":"Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem. 1986;261(13):6084\u20139.","journal-title":"J Biol Chem."},{"issue":"13","key":"707_CR20","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1073\/pnas.83.13.4913","volume":"83","author":"I Grundke-Iqbal","year":"1986","unstructured":"Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A. 1986;83(13):4913\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"707_CR21","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/ana.410220412","volume":"22","author":"B Wolozin","year":"1987","unstructured":"Wolozin B, Davies P. Alzheimer-related neuronal protein A68: specificity and distribution. Ann Neurol. 1987;22(4):521\u20136.","journal-title":"Ann Neurol"},{"issue":"2","key":"707_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0304-3940(99)00476-0","volume":"270","author":"K Ishiguro","year":"1999","unstructured":"Ishiguro K, Ohno H, Arai H, Yamaguchi H, Urakami K, Park JM, et al. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer\u2019s disease. Neurosci Lett. 1999;270(2):91\u20134.","journal-title":"Neurosci Lett"},{"issue":"5","key":"707_CR23","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1111\/j.1471-4159.1993.tb09823.x","volume":"61","author":"M Vandermeeren","year":"1993","unstructured":"Vandermeeren M, Mercken M, Vanmechelen E, Six J, van de Voorde A, Martin JJ, et al. Detection of tau proteins in normal and Alzheimer\u2019s disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem. 1993;61(5):1828\u201334.","journal-title":"J Neurochem"},{"issue":"3","key":"707_CR24","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/BF02815140","volume":"26","author":"K Blennow","year":"1995","unstructured":"Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol. 1995;26(3):231\u201345.","journal-title":"Mol Chem Neuropathol"},{"issue":"3","key":"707_CR25","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0304-3940(00)01178-2","volume":"287","author":"R Kohnken","year":"2000","unstructured":"Kohnken R, Buerger K, Zinkowski R, Miller C, Kerkman D, DeBernardis J, et al. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer\u2019s disease patients. Neurosci Lett. 2000;287(3):187\u201390.","journal-title":"Neurosci Lett"},{"issue":"3","key":"707_CR26","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1136\/jnnp.64.3.298","volume":"64","author":"N Andreasen","year":"1998","unstructured":"Andreasen N, Vanmechelen E, Van de Voorde A, Davidsson P, Hesse C, Tarvonen S, et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer\u2019s disease: a community based follow up study. J Neurol Neurosurg Psychiatry. 1998;64(3):298\u2013305.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"707_CR27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0304-3940(00)01036-3","volume":"285","author":"E Vanmechelen","year":"2000","unstructured":"Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett. 2000;285(1):49\u201352.","journal-title":"Neurosci Lett"},{"issue":"1","key":"707_CR28","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1001\/archpsyc.61.1.95","volume":"61","author":"H Hampel","year":"2004","unstructured":"Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry. 2004;61(1):95\u2013102.","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"707_CR29","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673\u201384.","journal-title":"Lancet Neurol"},{"issue":"5","key":"707_CR30","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol. 2021;141(5):709\u201324.","journal-title":"Acta Neuropathol"},{"issue":"12","key":"707_CR31","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton NJ, Janelidze S, Mattsson-Carlgren N, Binette AP, Strandberg O, Brum WS, et al. Differential roles of Abeta42\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring. Nat Med. 2022;28(12):2555\u201362.","journal-title":"Nat Med"},{"key":"707_CR32","doi-asserted-by":"publisher","first-page":"103836","DOI":"10.1016\/j.ebiom.2022.103836","volume":"76","author":"NJ Ashton","year":"2022","unstructured":"Ashton NJ, Benedet AL, Pascoal TA, Karikari TK, Lantero-Rodriguez J, Brum WS, et al. Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer\u2019s disease. EBioMedicine. 2022;76:103836.","journal-title":"EBioMedicine"},{"issue":"9","key":"707_CR33","first-page":"1797","volume":"28","author":"M Mila-Aloma","year":"2022","unstructured":"Mila-Aloma M, Ashton NJ, Shekari M, Salvado G, Ortiz-Romero P, Montoliu-Gaya L, et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-beta pathology in preclinical Alzheimer\u2019s disease. Nat Med. 2022;28(9):1797\u2013801.","journal-title":"Nat Med"},{"issue":"1","key":"707_CR34","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1038\/s41467-020-15436-0","volume":"11","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Stomrud E, Smith R, Palmqvist S, Mattsson N, Airey DC, et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer\u2019s disease. Nat Commun. 2020;11(1):1683.","journal-title":"Nat Commun"},{"issue":"8","key":"707_CR35","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative accuracy of plasma phospho-tau217 for alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772\u201381.","journal-title":"JAMA"},{"issue":"2","key":"707_CR36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/alzrt163","volume":"5","author":"H Zetterberg","year":"2013","unstructured":"Zetterberg H, Wilson D, Andreasson U, Minthon L, Blennow K, Randall J, et al. Plasma tau levels in Alzheimer\u2019s disease. Alzheimers Res Ther. 2013;5(2):9.","journal-title":"Alzheimers Res Ther"},{"issue":"12","key":"707_CR37","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.jalz.2016.06.001","volume":"12","author":"JL Dage","year":"2016","unstructured":"Dage JL, Wennberg AMV, Airey DC, Hagen CE, Knopman DS, Machulda MM, et al. Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort. Alzheimers Dement. 2016;12(12):1226\u201334.","journal-title":"Alzheimers Dement"},{"issue":"17","key":"707_CR38","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1212\/WNL.0000000000003246","volume":"87","author":"N Mattsson","year":"2016","unstructured":"Mattsson N, Zetterberg H, Janelidze S, Insel PS, Andreasson U, Stomrud E, et al. Plasma tau in Alzheimer disease. Neurology. 2016;87(17):1827\u201335.","journal-title":"Neurology"},{"issue":"7","key":"707_CR39","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/alz.12283","volume":"17","author":"J Simren","year":"2021","unstructured":"Simren J, Leuzy A, Karikari TK, Hye A, Benedet AL, Lantero-Rodriguez J, et al. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 2021;17(7):1145\u201356.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"707_CR40","doi-asserted-by":"publisher","first-page":"6024","DOI":"10.1038\/s41467-020-19543-w","volume":"11","author":"JP Chhatwal","year":"2020","unstructured":"Chhatwal JP, Schultz AP, Dang Y, Ostaszewski B, Liu L, Yang HS, et al. Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals. Nat Commun. 2020;11(1):6024.","journal-title":"Nat Commun"},{"issue":"5","key":"707_CR41","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/ana.25885","volume":"88","author":"D Mengel","year":"2020","unstructured":"Mengel D, Janelidze S, Glynn RJ, Liu W, Hansson O, Walsh DM. Plasma NT1 tau is a specific and early marker of alzheimer\u2019s disease. Ann Neurol. 2020;88(5):878\u201392.","journal-title":"Ann Neurol"},{"issue":"2","key":"707_CR42","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/brain\/awz346","volume":"143","author":"K Blennow","year":"2020","unstructured":"Blennow K, Chen C, Cicognola C, Wildsmith KR, Manser PT, Bohorquez SMS, et al. Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology. Brain. 2020;143(2):650\u201360.","journal-title":"Brain"},{"issue":"1","key":"707_CR43","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s13195-022-01142-0","volume":"14","author":"J Simren","year":"2022","unstructured":"Simren J, Brum WS, Ashton NJ, Benedet AL, Karikari TK, Kvartsberg H, et al. CSF tau368\/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals. Alzheimers Res Ther. 2022;14(1):192.","journal-title":"Alzheimers Res Ther"},{"key":"707_CR44","doi-asserted-by":"crossref","unstructured":"Lantero-Rodriguez J, Tissot C, Snellman A, Servaes S, Benedet AL, Rahmouni N, et al. Plasma and CSF concentrations of N-terminal tau fragments associate with in vivo neurofibrillary tangle burden. Alzheimers Dement. 2023.","DOI":"10.1002\/alz.13119"},{"issue":"7","key":"707_CR45","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1002\/alz.12907","volume":"19","author":"G Salvad\u00f3","year":"2023","unstructured":"Salvado G, Larsson V, Cody KA, Cullen NC, Jonaitis EM, Stomrud E, et al. Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: a multi-cohort study. Alzheimers Dement. 2023;19(7):2943\u201355.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"707_CR46","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med. 2020;26(3):379\u201386.","journal-title":"Nat Med"},{"issue":"8","key":"707_CR47","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1001\/jamaneurol.2022.1740","volume":"79","author":"S Janelidze","year":"2022","unstructured":"Janelidze S, Christian BT, Price J, Laymon C, Schupf N, Klunk WE, et al. Detection of brain tau pathology in down syndrome using plasma biomarkers. JAMA Neurol. 2022;79(8):797\u2013807.","journal-title":"JAMA Neurol"},{"issue":"6","key":"707_CR48","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","volume":"27","author":"S Palmqvist","year":"2021","unstructured":"Palmqvist S, Tideman P, Cullen N, Zetterberg H, Blennow K, Alzheimer\u2019s Disease Neuroimaging I, et al. Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med. 2021;27(6):1034\u201342.","journal-title":"Nat Med"},{"issue":"1","key":"707_CR49","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41467-017-01150-x","volume":"8","author":"S Palmqvist","year":"2017","unstructured":"Palmqvist S, Scholl M, Strandberg O, Mattsson N, Stomrud E, Zetterberg H, et al. Earliest accumulation of beta-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun. 2017;8(1):1214.","journal-title":"Nat Commun"},{"issue":"1","key":"707_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, et al. The centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11(1):1-15 e1-4.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"707_CR51","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","volume":"13","author":"CR Jack Jr","year":"2017","unstructured":"Jack CR Jr, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, et al. Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease. Alzheimers Dement. 2017;13(3):205\u201316.","journal-title":"Alzheimers Dement"},{"issue":"Pt 12","key":"707_CR52","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1093\/brain\/awv283","volume":"138","author":"CR Jack Jr","year":"2015","unstructured":"Jack CR Jr, Wiste HJ, Weigand SD, Knopman DS, Mielke MM, Vemuri P, et al. Different definitions of neurodegeneration produce similar amyloid\/neurodegeneration biomarker group findings. Brain. 2015;138(Pt 12):3747\u201359.","journal-title":"Brain"},{"issue":"8","key":"707_CR53","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2014.803","volume":"71","author":"MC Donohue","year":"2014","unstructured":"Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014;71(8):961\u201370.","journal-title":"JAMA Neurol"},{"issue":"11","key":"707_CR54","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1093\/brain\/awaa286","volume":"143","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren N, Janelidze S, Palmqvist S, Cullen N, Svenningsson AL, Strandberg O, et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer\u2019s disease. Brain. 2020;143(11):3234\u201341.","journal-title":"Brain"},{"issue":"8","key":"707_CR55","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/jamaneurol.2020.0989","volume":"77","author":"A Leuzy","year":"2020","unstructured":"Leuzy A, Smith R, Ossenkoppele R, Santillo A, Borroni E, Klein G, et al. Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders. JAMA Neurol. 2020;77(8):955\u201365.","journal-title":"JAMA Neurol"},{"issue":"1","key":"707_CR56","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jamaneurol.2023.4596","volume":"81","author":"N Mattsson-Carlgren","year":"2023","unstructured":"Mattsson-Carlgren N, Collij LE, Stomrud E, Pichet Binette A, Ossenkoppele R, Smith R, et al. Plasma biomarker strategy for selecting patients with Alzheimer disease for antiamyloid Immunotherapies. JAMA Neurol. 2023;81(1):69\u201378.","journal-title":"JAMA Neurol"},{"issue":"16","key":"707_CR57","doi-asserted-by":"publisher","first-page":"eaaz2387","DOI":"10.1126\/sciadv.aaz2387","volume":"6","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren N, Andersson E, Janelidze S, Ossenkoppele R, Insel P, Strandberg O, et al. Abeta deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer\u2019s disease. Sci Adv. 2020;6(16):eaaz2387.","journal-title":"Sci Adv"},{"issue":"2","key":"707_CR58","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaneurol.2020.4201","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze S, Berron D, Smith R, Strandberg O, Proctor NK, Dage JL, et al. Associations of Plasma phospho-tau217 levels with tau positron emission tomography in early Alzheimer disease. JAMA Neurol. 2021;78(2):149\u201356.","journal-title":"JAMA Neurol"},{"issue":"3","key":"707_CR59","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat Med. 2020;26(3):387\u201397.","journal-title":"Nat Med"},{"issue":"8","key":"707_CR60","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","volume":"14","author":"MM Mielke","year":"2018","unstructured":"Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, et al. Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 2018;14(8):989\u201397.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"707_CR61","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","volume":"80","author":"J Therriault","year":"2023","unstructured":"Therriault J, Vermeiren M, Servaes S, Tissot C, Ashton NJ, Benedet AL, et al. Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs tau positron emission tomography. JAMA Neurol. 2023;80(2):188\u201399.","journal-title":"JAMA Neurol"},{"issue":"6","key":"707_CR62","doi-asserted-by":"publisher","first-page":"e14022","DOI":"10.15252\/emmm.202114022","volume":"13","author":"N Mattsson-Carlgren","year":"2021","unstructured":"Mattsson-Carlgren N, Janelidze S, Bateman RJ, Smith R, Stomrud E, Serrano GE, et al. Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Mol Med. 2021;13(6):e14022.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"707_CR63","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13024-022-00578-0","volume":"17","author":"ME Murray","year":"2022","unstructured":"Murray ME, Moloney CM, Kouri N, Syrjanen JA, Matchett BJ, Rothberg DM, et al. Global neuropathologic severity of Alzheimer\u2019s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels. Mol Neurodegener. 2022;17(1):85.","journal-title":"Mol Neurodegener"},{"key":"707_CR64","doi-asserted-by":"crossref","unstructured":"Salvad\u00f3 G, Ossenkoppele R, Ashton NJ, Beach TG, Serrano GE, Zetterberg H, et al. Specific associations between plasma biomarkers and post-mortem amyloid plaque and neurofibrillary tau tangle loads. medRxiv. 2022:2022.08.22.22279052.","DOI":"10.1101\/2022.08.22.22279052"},{"issue":"12","key":"707_CR65","doi-asserted-by":"publisher","first-page":"e11170","DOI":"10.15252\/emmm.201911170","volume":"11","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist S, Insel PS, Stomrud E, Janelidze S, Zetterberg H, Brix B, et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer\u2019s disease. EMBO Mol Med. 2019;11(12):e11170.","journal-title":"EMBO Mol Med"},{"issue":"5","key":"707_CR66","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422\u201333.","journal-title":"Lancet Neurol"},{"issue":"5","key":"707_CR67","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","volume":"71","author":"PT Nelson","year":"2012","unstructured":"Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71(5):362\u201381.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"6","key":"707_CR68","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/jnen\/nlw026","volume":"75","author":"A Serrano-Pozo","year":"2016","unstructured":"Serrano-Pozo A, Qian J, Muzikansky A, Monsell SE, Montine TJ, Frosch MP, et al. Thal amyloid stages do not significantly impact the correlation between neuropathological change and cognition in the alzheimer disease continuum. J Neuropathol Exp Neurol. 2016;75(6):516\u201326.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"10","key":"707_CR69","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1001\/jamaneurol.2022.2793","volume":"79","author":"S Shcherbinin","year":"2022","unstructured":"Shcherbinin S, Evans CD, Lu M, Andersen SW, Pontecorvo MJ, Willis BA, et al. Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 2022;79(10):1015\u201324.","journal-title":"JAMA Neurol"},{"issue":"2","key":"707_CR70","first-page":"221","volume":"9","author":"J Cummings","year":"2022","unstructured":"Cummings J, Rabinovici GD, Atri A, Aisen P, Apostolova LG, Hendrix S, et al. Aducanumab: appropriate use recommendations update. J Prev Alzheimers Dis. 2022;9(2):221\u201330.","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"707_CR71","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"issue":"18","key":"707_CR72","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in early Alzheimer\u2019s Disease. N Engl J Med. 2021;384(18):1691\u2013704.","journal-title":"N Engl J Med"},{"issue":"12","key":"707_CR73","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson O, Edelmayer RM, Boxer AL, Carrillo MC, Mielke MM, Rabinovici GD, et al. The Alzheimer\u2019s association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 2022;18(12):2669\u201386.","journal-title":"Alzheimers Dement"},{"issue":"12","key":"707_CR74","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1093\/brain\/awx243","volume":"140","author":"A Bejanin","year":"2017","unstructured":"Bejanin A, Schonhaut DR, La Joie R, Kramer JH, Baker SL, Sosa N, et al. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer\u2019s disease. Brain. 2017;140(12):3286\u2013300.","journal-title":"Brain"},{"issue":"524","key":"707_CR75","doi-asserted-by":"publisher","first-page":"eaau5732","DOI":"10.1126\/scitranslmed.aau5732","volume":"12","author":"R La Joie","year":"2020","unstructured":"La Joie R, Visani AV, Baker SL, Brown JA, Bourakova V, Cha J, et al. Prospective longitudinal atrophy in Alzheimer\u2019s disease correlates with the intensity and topography of baseline tau-PET. Sci Transl Med. 2020;12(524):eaau5732.","journal-title":"Sci Transl Med"},{"issue":"4","key":"707_CR76","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","volume":"80","author":"N Mattsson-Carlgren","year":"2023","unstructured":"Mattsson-Carlgren N, Salvado G, Ashton NJ, Tideman P, Stomrud E, Zetterberg H, et al. Prediction of longitudinal cognitive decline in preclinical Alzheimer Disease using plasma biomarkers. JAMA Neurol. 2023;80(4):360\u20139.","journal-title":"JAMA Neurol"},{"issue":"2","key":"707_CR77","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaneurol.2021.4654","volume":"79","author":"A Leuzy","year":"2022","unstructured":"Leuzy A, Smith R, Cullen NC, Strandberg O, Vogel JW, Binette AP, et al. Biomarker-based prediction of longitudinal tau positron emission tomography in Alzheimer Disease. JAMA Neurol. 2022;79(2):149\u201358.","journal-title":"JAMA Neurol"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-024-00707-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-024-00707-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-024-00707-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T05:03:40Z","timestamp":1708146220000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-024-00707-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,17]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["707"],"URL":"https:\/\/doi.org\/10.1186\/s13024-024-00707-x","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,17]]},"assertion":[{"value":"26 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants gave written informed consent and ethical approval was granted by the Regional Ethical Committee in Lund, Sweden.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KB has served as a consultant and at advisory boards for Acumen, ALZPath, BioArctic, Biogen, Eisai, Julius Clinical, Lilly, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for Biogen, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). OH has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past 2\u00a0years, he has received consultancy\/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Genentech, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. JLR, GS, AES, LMG, WSB, ALB, NMC, PT, SJ, SP, ES and NJA report no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}